Molecular Bank
a:1:{s:7:"English";s:19915:"
PCMD Molecular Bank: A National Resource for Drug Discovery and Development
Compounds libraries are being develop all around the world to store millions of potential drug candidates. Proper management of the compound collection is the foundation of any quality compound screening program.
The first Molecular Bank of Pakistan was established in 2006 to collect and organize natural and synthetic compounds, isolated or synthesized at the ICCBS, as well as in other collaborating laboratories.
Compound collection is contributed by the isolation and synthetic research groups of the ICCBS. Molecular Bank now has a collection of around 18,000 fully characterized chemical compounds. The main activities include receiving compounds with their complete information, evaluation of their purities by TLC, and HPLC, and 1D and 2D NMR.
Compounds preserved in screw capped glass vials with specific barcodes at -20 ˚C.
It also include organizing them into various categories, depending on source and structural types, and finally, arranging them on the basis of various biological activities.
It is prudent for a large organization to have a chemically intelligent database and compatible management of the compounds for further research and development. In PCMD Molecular Bank, compounds are managed with barcodes and relational database. Chemfinder database is used to maintain chemical, structural and biological information for ready reference. Molecular Bank Database is home-based, which is only accessible to the ICCBS researchers through institutional network.
Chemfinder for database creates SDF. SDF is the structure data file which shows the structural information along with chemical and biological data with respect to the structure identification code (structure ID).
The PCMD has established state-of-the-art biological /pharmacological screening and research facilities as a support service to the researchers of the ICCBS, and other collaborating institutions. The screening facility of the center is managed by the Molecular Bank, and supervised by qualified and dedicated staff. We offer to evaluate pure compounds (Natural /Synthetic) for potential activity against many cellular and molecular dysfunctions, such as cancers, Alzheimer’s and Parkinson’s diseases, obesity, diabetes, inflammation, arthritis, cataract, arthrosclerosis, malaria, skin infections, resistant microbial infections, oxidative stress, rheumatoid arthritis, tropical diseases, immunological disorders, etc. These assays are directly relevant to drug discovery and development, and can lead to major discoveries. In case of any promising active molecular discovery, collaboration is established for joint patent or publication on mutually agreed terms.
Following biological assays are currently available:
If you are interested in evaluation of biological activity of your compound, kindly send to us at least 10 mg of the compound with 99% purity in pre-weighed Epppendrof tubes or vials, along with relevant information, such as structure, molecular weight, solubility, source, and class of compound, stability, potential hazard, and relevant reference.
We are pleased to invite researchers, home and abroad, to submit their purified/ identified natural products for any of the above cited assays. The service will be rendered free of cost on the basis of mutual confidentiality agreement, and collaborations. On completion of the studies, you will receive the result data electronically or by mail on a prescribed form.
1. Sample Submission Form for Collaborators (Outside Pakistan)
2. Sample Submission Form / H.E.C. Analysis
Ms. Sadia Siddiq
Manager, Molecular Bank
Dr. Panjwani Center for Molecular Medicine and Drug Research
(International Center for Chemical and Biological Sciences)
University of Karachi-75270, Pakistan
Tel.No:009221111222292, 00922199261701-2,
Fax: 00922199261713, 00922134819018
E-mail: sadiabio@yahoo.com
";}
The first Molecular Bank of Pakistan was established in 2006 to collect and organize natural and synthetic compounds, isolated or synthesized at the ICCBS, as well as in other collaborating laboratories.
| Molecular Bank Stock & Library Design: |
Compound collection is contributed by the isolation and synthetic research groups of the ICCBS. Molecular Bank now has a collection of around 18,000 fully characterized chemical compounds. The main activities include receiving compounds with their complete information, evaluation of their purities by TLC, and HPLC, and 1D and 2D NMR.
Compounds preserved in screw capped glass vials with specific barcodes at -20 ˚C.
It also include organizing them into various categories, depending on source and structural types, and finally, arranging them on the basis of various biological activities.
 |
 |
| Description of the Database & Data Files: |
It is prudent for a large organization to have a chemically intelligent database and compatible management of the compounds for further research and development. In PCMD Molecular Bank, compounds are managed with barcodes and relational database. Chemfinder database is used to maintain chemical, structural and biological information for ready reference. Molecular Bank Database is home-based, which is only accessible to the ICCBS researchers through institutional network.
Chemfinder for database creates SDF. SDF is the structure data file which shows the structural information along with chemical and biological data with respect to the structure identification code (structure ID).
| Bioassay Facilities: |
The PCMD has established state-of-the-art biological /pharmacological screening and research facilities as a support service to the researchers of the ICCBS, and other collaborating institutions. The screening facility of the center is managed by the Molecular Bank, and supervised by qualified and dedicated staff. We offer to evaluate pure compounds (Natural /Synthetic) for potential activity against many cellular and molecular dysfunctions, such as cancers, Alzheimer’s and Parkinson’s diseases, obesity, diabetes, inflammation, arthritis, cataract, arthrosclerosis, malaria, skin infections, resistant microbial infections, oxidative stress, rheumatoid arthritis, tropical diseases, immunological disorders, etc. These assays are directly relevant to drug discovery and development, and can lead to major discoveries. In case of any promising active molecular discovery, collaboration is established for joint patent or publication on mutually agreed terms.
Following biological assays are currently available:
| NAME OF BIOASSAYS | |
| (A) | Enzyme Inhibition Studies: |
| (i) | Cholinesterases (AChE and BchE Inhibition) |
| (ii) | Phosphodiesetrases Inhibition |
| (iii) | Urease Inhibition |
| (iv) | β-Glucuronidase Inhibition |
| (v) | Prolyl Endopeptidase Inhibition |
| (vi) | Thymidine Phosphorylase Inhibition |
| (vii) | Carbonic Anhydrase Inhibition |
| (viii) | Tyrosinase Inhibition |
| (ix) | α-Chymotrpsin Inhibition |
| (x) | α-Glucosidase Inhibition |
| (xi) | Dipeptidyl peptidase IV Inhibition |
| (xii) | Lipase Inhibition |
| (xii ) | Xanthine Oxidase Inhibition |
| (xiii) | Human Aromatase Inhibition |
| (B) | Antioxidant Studies: |
| (i) | DPPH Radical Scavenging Assay |
| (ii) | Superoxide Anion Scavenging Assay |
| (iii) | Nitric Oxide Scavenging Assay |
| (iv) | Fe++ Chelating Assay |
| (C) | Antiglycation Assays |
| (D) | Antibiofilm Assays |
| (i) | Fungal (Candida parapsilosis) |
| (ii) | Bacterial (Salmonella typhimurium) |
| (E) | Anti-Inflammatory (Respiratory Burst Assay) |
| (F) | Larvicidal Assay for Aedes aegypti (Dengue fever vector) |
| (G) | Bench-top Bioassays: |
| (i) | Antibacterial Assay |
| (ii) | Antifungal Assay |
| (iii) | Brine-shrimp Lethality Assay |
| (iv) | Phytotoxicity Assay |
| (v) | Insecticidal Assay |
| (vi) | Leishmanicidal Assay |
| (H) | MDR Bacterial and Fungal Assays |
| (I) | Cytotoxicity Assays against normal cell lines (Including human cells) |
| (J) | Cancer Cell line Assays : |
| (i) | PC3 (Human Prostate Cancer Cell Line) |
| (ii) | HeLa (Cervical Cancer Cell Line) |
| (iii) | MCF-7 (Estrogen/Progesterone Positive Breast Cancer Cell Line) |
| (iv) | MDA-MB 231(Triple Negative Breast Cancer Cell Line) |
| (v) | H460 ( Non-Small Cell Lung Carcinoma Cell Line) |
| (vi) | K562 (Chronic Myeloid Leukemia Cell Line) |
| (vii) | BT-474 (Human Breast Carcinoma Cell Line) |
| (viii) | AU-565 (Human Breast Cancer Cell Line) |
| (K) | MC3T3-E1 (Osteoblast Proliferation Assay) |
| Compounds Submission: |
If you are interested in evaluation of biological activity of your compound, kindly send to us at least 10 mg of the compound with 99% purity in pre-weighed Epppendrof tubes or vials, along with relevant information, such as structure, molecular weight, solubility, source, and class of compound, stability, potential hazard, and relevant reference.
We are pleased to invite researchers, home and abroad, to submit their purified/ identified natural products for any of the above cited assays. The service will be rendered free of cost on the basis of mutual confidentiality agreement, and collaborations. On completion of the studies, you will receive the result data electronically or by mail on a prescribed form.
| Download Forms: |
1. Sample Submission Form for Collaborators (Outside Pakistan)
2. Sample Submission Form / H.E.C. Analysis
| Contact Us: |
Ms. Sadia Siddiq
Manager, Molecular Bank
Dr. Panjwani Center for Molecular Medicine and Drug Research
(International Center for Chemical and Biological Sciences)
University of Karachi-75270, Pakistan
Tel.No:009221111222292, 00922199261701-2,
Fax: 00922199261713, 00922134819018
E-mail: sadiabio@yahoo.com